Therapies for the treatment of onychomycosis

Clinics in Dermatology

Volumn 31, Issue 5, 2013, Pages 544-554

  Gupta, Aditya K ^a,b   Paquet, Maryse ^b   Simpson, Fiona C ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; ASTEMIZOLE; CICLOPIROX; CISAPRIDE; COUMARIN; DOFETILIDE; ELETRIPTAN; ERGOMETRINE; ERGOT ALKALOID; ERGOTAMINE; FELODIPINE; FLUCONAZOLE; ITRACONAZOLE; LEVACETYLMETHADOL; METHADONE; METHYLERGOMETRINE; MEVINOLIN; MIDAZOLAM; NISOLDIPINE; PIMOZIDE; PLACEBO; PYRROLE DERIVATIVE; QUINIDINE; SIMVASTATIN; TERBINAFINE; TERFENADINE; TRIAZOLAM; UNINDEXED DRUG; WARFARIN;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CHEMICAL AVULSION; CHEMICAL PROCEDURES; CONCENTRATION RESPONSE; COST EFFECTIVENESS ANALYSIS; DEBRIDEMENT; DEPRESSION; DERMATOLOGICAL PROCEDURE; DERMATOPHYTE; DEVICE THERAPY; DIABETIC PATIENT; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; FUNGICIDAL ACTIVITY; HIGH RISK POPULATION; HUMAN; HYPOGLYCEMIA; INGROWN NAIL; LIVER FAILURE; LOW LEVEL LASER THERAPY; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MOULD; NAIL AVULSION; NAIL BED; NEUTROPENIA; NOTE; ONYCHOMYCOSIS; POPULATION RESEARCH; PRIORITY JOURNAL; PRURITUS; RISK BENEFIT ANALYSIS; RISK FACTOR; SKIN BURNING SENSATION; SKIN IRRITATION; SKIN PAIN; SKIN REDNESS; SMELLING DISORDER; STEVENS JOHNSON SYNDROME; SURGICAL APPROACH; TASTE DISORDER; TINEA PEDIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREATMENT OUTCOME; YEAST;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; DEBRIDEMENT; FLUCONAZOLE; HUMANS; ITRACONAZOLE; LASER THERAPY; MORPHOLINES; NAPHTHALENES; ONYCHOMYCOSIS; PYRIDONES;

EID: 84884695526     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2013.06.011     Document Type: Note

References (103)

1. Gupta A.K., Simpson F.C. New therapeutic options for onychomycosis. Expert Opin Pharmacother 2012, 13:1131-1142.
2. Gupta A.K., Kohli Y. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br J Dermatol 2003, 149:296-305.
3. Figueiredo V.T., de Assis Santos D., Resende M.A., et al. Identification and in vitro antifungal susceptibility testing of 200 clinical isolates of Candida spp. responsible for fingernail infections. Mycopathologia 2007, 164:27-33.
4. Faergemann J., Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol 2003, 149:1-4.
5. Markinson B.C., Monter S.I., Cabrera G. Traditional approaches to treatment of onychomycosis. J Am Podiatr Med Assoc 1997, 87:551-556.
6. Di Chiacchio N., Kadunc B.V., de Almeida A.R., et al. Nail abrasion. J Cosmet Dermatol 2003, 2:150-152.
7. Pandhi D., Verma P. Nail avulsion: indications and methods (surgical nail avulsion). Ind J Dermatol Venereol Leprol 2012, 78:299-308.
8. Baran R., Hay R.J., Garduno J.I. Review of antifungal therapy and the severity index for assessing onychomycosis: part I. J Dermatolog Treat 2008, 19:72-81.
9. Baran R. Chemical avulsion with urea nail lacquer. J Dermatolog Treat 2002, 13:161-164.
10. Baran R., Coquard F. Combination of fluconazole and urea in a nail lacquer for treating onychomycosis. J Dermatolog Treat 2005, 16:52-55.
11. Rollman O. Treatment of onychomycosis by partial nail avulsion and topical miconazole. Dermatologica 1982, 165:54-61.
12. Tosti A., Piraccini B.M., Lorenzi S. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol 2000, 42:217-224.
13. Grover C., Bansal S., Nanda S., et al. Combination of surgical avulsion and topical therapy for single nail onychomycosis: a randomized controlled trial. Br J Dermatol 2007, 157:364-368.
14. Lai W.Y., Tang W.Y.M., Loo S.K.F., et al. Clinical characteristics and treatment outcomes of patients undergoing nail avulsion surgery for dystrophic nails. Hong Kong Med J 2011, 17:127-131.
15. Flagothier C., Piérard-Franchimont C., Piérard G.E. New insights into the effect of amorolfine nail lacquer. Mycoses 2005, 48:91-94.
16. Iorizzo M., Piraccini B.M., Tosti A. Today's treatments options for onychomycosis. J Dtsch Dermatol Ges 2010, 8:875-879.
17. Lecha M., Effendy I. Feuilhade de Chauvin M, et al. Treatment options-development of consensus guidelines. J Eur Acad Dermatol Venereol 2005, 19:25-33.
18. Singal A., Khanna D. Onychomycosis: diagnosis and management. Ind J Dermatol Venereol Leprol 2011, 77:659-672.
19. Gupta A.K., Ryder J.E., Baran R. The use of topical therapies to treat onychomycosis. Dermatol Clin 2003, 21:481-489.
20. Medicines and Healthcare Products Regulatory Agency Public Assessment Report Decentralised Procedure: Amorolfine 5% W/V Nail Lacquer Available at:, Accessed August 9, 2012. http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con129125.pdf.
21. Hsu M.M.-L. Rapid response of distal subungual onychomycosis to 5% amorolfine nail lacquer in a 20-month-old healthy infant. Pediatr Dermatol 2006, 23:410-411.
22. Peña-Penabad C., García-Silva J., Almagro M., et al. Superficial white onychomycosis in a 3-year-old human immunodeficiency virus-infected child. J Eur Acad Dermatol Venereol 2001, 15:51-53.
23. Kruk M.E., Schwalbe N. The relation between intermittent dosing and adherence: preliminary insights. Clin Therapeutics 2006, 28:1989-1995.
24. Reinel D. Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use. Dermatology 1992, 184:21-24.
25. Mensing H., Polak-Wyss A., Splanemann V. Determination of the subungual antifungal activity of amorolfine after 1 month's treatment in patients with onychomycosis: comparison of two nail lacquer formulations. Clin Exp Dermatol 1992, 17:29-32.
26. Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992, 17:41-43.
27. Reinel D., Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol 1992, 17:44-49.
28. Bohn M., Kraemer K.T. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000, 43:S57-S69.
29. Subissi A., Monti D., Togni G., et al. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs 2010, 70:2133-2152.
30. Dermik Laboratories Penlac Nail Lacquer (Ciclopirox) Topical Solution, 8% Available at:, Accessed June 1, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21022s004lbl.pdf.
31. Baran R., Tosti A., Hartmane I., et al. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol 2009, 23:773-781.
32. Sardana K., Garg V.K., Manchanda V., et al. Congenital candidal onychomycoses: effective cure with ciclopirox olamine 8% nail lacquer. Br J Dermatol 2006, 154:573-575.
33. Zac R.I., Café M.E.M., Neves D.R., et al. Onychomycosis in a very young child. Pediatr Dermatol 2009, 26:761-762.
34. Sachdeva S., Gupta S., Prasher P., et al. Trichophyton rubrum onychomycosis in a 10-week-old infant. Int J Dermatol 2010, 49:108-109.
35. Ploysangam T., Lucky A.W. Childhood white superficial onychomycosis caused by Trichophyton rubrum: report of seven cases and review of the literature. J Am Acad Dermatol 1997, 36:29-32.
36. Valeant Product monograph Penlac (Ciclopirox Topical Solution, 8% w/w) Nail Lacquer Available at:, Accessed August 21, 2012. http://webprod3.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=73535.
37. Thomas J., Jacobson G.A., Narkowicz C.K., et al. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther 2010, 35:497-519.
38. Elewski B.E. Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol 1993, 28:S28-S34.
39. Van Duyn Graham L., Elewski B.E. Recent updates in oral terbinafine: its use in onychomycosis and tinea capitis in the US. Mycoses 2011, 54:e679-e685.
40. Novartis Pharmaceuticals Corporation Lamisil tablets (terbinafine) label information Available at:, Accessed May 30, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020539s021lbl.pdf.
41. Gupta A.K., Skinner A.R. Onychomycosis in children: a brief overview with treatment strategies. Pediatr Dermatol 2004, 21:74-79.
42. Jones T.C. Overview of the use of terbinafine (Lamisil) in children. Br J Dermatol 1995, 132:683-689.
43. Ginter-Hanselmayer G., Weger W., Smolle J. Onychomycosis: a new emerging infectious disease in childhood population and adolescents. Report on treatment experience with terbinafine and itraconazole in 36 patients. J Eur Acad Dermatol Venereol 2008, 22:470-475.
44. Novartis Pharmaceuticals Corporation Lamisil oral granules (terbinafine) label information Available at:, Accessed May 30, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022071s007lbl.pdf.
45. Darkes M.J.M., Scott L.J., Goa K.L. Terbinafine: a review of its use in onychomycosis in adults. Am J Clin Dermatol 2003, 4:39-65.
46. Yin Z., Xu J., Luo D. A meta-analysis comparing long-term recurrences of toenail onychomycosis after successful treatment with terbinafine versus itraconazole. J Dermatolog Treat 2012, 23:449-452.
47. Matricciani L., Talbot K., Jones S. Safety and efficacy of tinea pedis and onychomycosis treatment in people with diabetes: a systematic review. J Foot Ankle Res 2011, 4:26.
48. Novartis Pharmaceuticals Corporation Lamisil tablets (terbinafine hydrochloride) Available at:, Accessed August 20, 2012. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2009-PI-00265-3.
49. Product monograph Lamisil (terbinafine hydrochloride) Novartis Pharmaceuticals Corporation, Available at:, Accessed August 21, 2012. http://webprod3.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=13990.
50. Katz H.I., Gupta A.K. Oral antifungal drug interactions. Dermatol Clin 1997, 15:535-544.
51. Gupta A.K., Shear N.H. Safety review of the oral antifungal agents used to treat superficial mycoses. Int J Dermatol 1999, 38:40-52.
52. Korting H.C., Schöllmann C. The significance of itraconazole for treatment of fungal infections of skin, nails and mucous membranes. J Dtsch Dermatol Ges 2009, 7:11-19.
53. Janssen Sporanox capsules product information Available at:, Accessed August 20, 2012. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-01501-3.
54. Ortho-McNeil-Janssen Pharmaceuticals Sporanox capsules (Itraconazole) label information Available at:, Accessed May 30, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020083s048s049s050lbl.pdf.
55. Ginter G. Mycoses in children: systemic treatment. Acta Dermatovenerol Ala Panonica Adriat 1998, 7:101-105.
56. Heikkilä H., Stubb S. Onychomycosis in children: treatment results of forty-seven patients. Acta Derm Venereol 2002, 82:484-485.
57. Sporanox oral solution (Itraconazole) label information Centocor Ortho Biotech, Available at:, Accessed May 30, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020657s028lbl.pdf.
58. De Doncker P.R., Scher R.K., Baran R.L., et al. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol 1997, 36:173-177.
59. Janssen Product monograph Sporanox itraconazole capsules 100 mg antifungal agent Available at:, Accessed August 22, 2012. http://webprod3.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=14518.
60. Trivedi N.A., Shah P.C. A meta-analysis comparing efficacy of continuous terbinafine with intermittent itraconazole for toenail onychomycosis. Indian J Dermatol 2010, 55:198-199.
61. Gupta A.K., Drummond-Main C., Paquet M. Evidence-based optimal fluconazole dosing regimen for onychomycosis treatment. J Dermatolog Treat 2013, 24:75-80.
62. Tosti A., Piraccini B.M., Lorenzi S., et al. Treatment of nondermatophyte mold and Candida onychomycosis. Dermatol Clin 2003, 21:491-497.
63. Aihara Y., Mori M., Yokota S. Successful treatment of onychomycosis with fluconazole in two patients with hyperimmunoglobulin E syndrome. Pediatr Dermatol 1996, 13:493-495.
64. Assaf R.R., Elewski B.E. Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. J Am Acad Dermatol 1996, 35:216-219.
65. Gupta A.K., Sibbald R.G., Lynde C.W., et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol 1997, 36:395-402.
66. Gianni C., Cerri A., Capsoni F., et al. Recurrent proximal white subungual onychomycosis associated with a defect of the polymorphonuclear chemotaxis. Eur J Dermatol 1999, 9:390-392.
67. Romano C., Papini M., Ghilardi A., et al. Onychomycosis in children: a survey of 46 cases. Mycoses 2005, 48:430-437.
68. Pfizer Diflucan tablets (fluconazole) label information Available at:, Accessed May 30, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s055,019950s059,020090s038lbl.pdf.
69. Pfizer Product information Diflucan (fluconazole) Available at:, Accessed August 20, 2012. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-03528-3.
70. Brown S.J. Efficacy of fluconazole for the treatment of onychomycosis. Ann Pharmacother 2009, 43:1684-1691.
71. Manevitch Z., Lev D., Hochberg M., et al. Direct antifungal effect of femtosecond laser on Trichophyton rubrum onychomycosis. Photochem Photobiol 2010, 86:476-479.
72. Pfizer Product monograph Diflucan one fluconazole capsule 150 mg Available at:, Accessed August 22, 2012. http://webprod3.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=17789.
73. Anderson R.R., Parrish J.A. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983, 220:524-527.
74. Vural E., Winfield H.L., Shingleton A.W., et al. The effects of laser irradiation on Trichophyton rubrum growth. Lasers Med Sci 2008, 23:349-353.
75. Fotona Inc. 510(k) Summary K113702. XP Nd:YAG Laser System Family, Fotona Inc Available at:, Accessed April 16, 2012. http://www.accessdata.fda.gov/cdrh_docs/pdf11/K113702.pdf.
76. Aerolase Inc. Skin Tightening and Hair Removal with LightPodNeo Available at:, Accessed June 8, 2012. http://www.aerolase.com/LightPodNeo.html#Specs.
77. Hochman L.G. Laser treatment of onychomycosis using a novel 0.65-millisecond pulsed Nd:YAG 1064-nm laser. J Cosmet Laser Ther 2011, 13:2-5.
78. Sciton Inc. 510(k) Summary K111483. JOULE ClearSense, Sciton Inc Available at:, Accessed December 20, 2011. http://www.accessdata.fda.gov/cdrh_docs/pdf11/K111483.pdf.
79. Waibel J. Introducing the Sciton ClearSense Accessory featuring the ClearToe treatment for Onychomycosis (For Non-U.S. Customers) Available at:, Accessed January 12, 2012. http://www.sciton.com/node/2388.
80. Pinpointe USA. 510(k) Summary K093547. PinPointe FootLaser, Pinpointe USA Inc Available at:, Accessed October 24, 2011. http://www.accessdata.fda.gov/cdrh_docs/pdf9/K093547.pdf.
81. Harris D.M., McDowell B.A., Strisower J. Laser treatment for toenail fungus. Proc of SPIE 2009, 7161:1-7.
82. Cutera Inc. 510(k) Summary K103626. GenesisPlus, Cutera Inc Available at:, Accessed October 24, 2011. http://www.accessdata.fda.gov/cdrh_docs/pdf10/K103626.pdf.
83. Weiss D. 3 Month Clinical Results using Sub-millisecond 1064 nm Nd:YAG Laser for the Treatment of Onychomycosis Available at:. http://conejofeet.com/wp-content/uploads/2011/06/David-Weiss-DPM-report.pdf.
84. Kimura U., Takeuchi K., Kinoshita A., et al. Treating onychomycoses of the toenail: clinical efficacy of the sub-millisecond 1,064 nm Nd: YAG laser using a 5 mm spot diameter. J Drugs Dermatol 2012, 11:496-504.
85. New Star Lasers Inc. 510(k) Summary K103338. CoolTouch Varia, New Star Lasers Inc Available at:, Accessed November 30, 2011. http://www.accessdata.fda.gov/cdrh_docs/pdf6/K060966.pdf.
86. CoolTouch Inc. CoolTouch CT3Plus Laser Specifications. Available at . Accessed June 8, 2012. http://www.cooltouch.com/CT3Plus_specifications.aspx.
87. Lutronic Corporation 510(k) Summary K113843. Freedom Laser System, Lutronic Corporation Available at:, Accessed October 1, 2012. http://www.accessdata.fda.gov/cdrh_docs/pdf11/K113843.pdf.
88. Alma Lasers 510(k) Summary K113810. Harmony, Alma Lasers Inc Available at:, Accessed March 19. http://www.accessdata.fda.gov/cdrh_docs/pdf11/K113810.pdf.
89. Light Age Inc 510(k) Summary K110370. Q-Clear, Light Age Available at:, Accessed October 24, 2011. http://www.accessdata.fda.gov/cdrh_docs/pdf11/K110370.pdf.
90. Landsman A.S., Robbins A.H., Angelini P.F., et al. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. J Am Podiatr Med Assoc 2010, 100:166-177.
91. Landsman A.S., Robbins A.H. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure: some follow-up observations at 270 days. J Am Podiatr Med Assoc 2012, 102:169-171.
92. ConBio Diode Laser Treatment of Onychomycosis Available at:, Accessed May 25, 2012. http://clinicaltrials.gov/ct2/show/NCT01452490.
93. Tausch I., Bräutigam M., Weidinger G., et al. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. The Lagos V Study Group. Br J Dermatol 1997, 136:737-742.
94. Gupta A.K., Ryder J.E., Johnson A.M. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004, 150:537-544.
95. Gupta A.K., Gregurek-Novak T., Konnikov N., et al. Itraconazole and terbinafine treatment of some nondermatophyte molds causing onychomycosis of the toes and a review of the literature. J Cutan Med Surg 2001, 5:206-210.
96. Lebwohl M.G., Daniel C.R., Leyden J., et al. Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis. Int J Dermatol 2001, 40:358-360.
97. Gianni C., Romano C. Clinical and histological aspects of toenail onychomycosis caused by Aspergillus spp.: 34 cases treated with weekly intermittent terbinafine. Dermatology 2004, 209:104-110.
98. Mishra M., Panda P., Tripathy S., et al. An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis. Ind J Dermatol Venereol Leprol 2005, 71:262-266.
99. Gupta A.K., Gregurek-Novak T. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology (Basel) 2001, 202:235-238.
100. Segal R., Kritzman A., Cividalli L., et al. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol 1996, 35:958-961.
101. Zaidi Z., Jafri N., Khan K., et al. Open label trial of the efficacy and tolerability of Lamisil (terbinafine) 500 mg once daily in the treatment of onychomycosis due to Candida. J Park Med Assoc 1996, 46:258-260.
102. Gupta A.K., De Doncker P., Haneke E. Itraconazole pulse therapy for the treatment of Candida onychomycosis. J Eur Acad Dermatol Venereol 2001, 15:112-115.
103. Warshaw E.M., Nelson D., Carver S.M., et al. A pilot evaluation of pulse itraconazole vs. terbinafine for treatment of Candida toenail onychomycosis. Int J Dermatol 2005, 44:785-788.